Ercüment GÜRLÜLER, Halil TÜRKAN, Özgen IŞIK, Mehmet Türkay KIRDAK, Mustafa Şehsuvar GÖKGÖZ

Meme Kanseri Hastalarında Tiroid Kanseri Açısından Risk Artışı Var Mıdır? Retrospektif Tek Merkez Deneyimi

Meme kanseri (MK) ve Tiroid Papiller Kanseri (TPK), kadınlarda en sık görülen iki kanser türü olarak bilinmektedir. MK tanısı olan hastalarda TPK gelişiminin ise normal popülasyona göre artış gösterdiği bilinmektedir. Ancak bu konudaki risk artışının değerlendirilmesi konusundaki çalışmalar sınırlıdır. Mevcut çalışma kapsamında, MK tanısı almış hastalarda TPK gelişiminin risk faktörlerinin değerlendirilmesi amaçlanmıştır. 2006 ve 2018 yılları arasında TPK nedeniyle opere edilmiş hastaların verisi endokrin cerrahi veri tabanından retrospektif olarak derlendi. Öncesinde MK tanısı olan ve TPK nedeniyle tiroidektomi uygulanmış 23 hasta çalışma grubuna dahil edildi. Aynı sayıda, başka malignite öyküsü olmayan ve TPK nedeniyle opere olmuş hasta kontrol grubunu oluşturdu. İki grup aile öyküsü, demografik veriler, laboratuvar değerleri, cerrahi özellikler ve hastalık evresi yönünden karşılaştırıldı. Ortalama yaşı 55,35± 9,2 olan 46 kadın hasta dahil edildi. MK sonrası TPK tanısı için geçen median süre 27 (0-275) aydı. İki grup arasında yaş, vücut kitle indeksi, menstruel durum, hipertiroidi varlığı, otoantikor pozitifliği açısından istatistiksel olarak anlamlı bir fark bulunmazken, aile öyküsü pozitifliği MK+TPK grubunda, TPK grubuna göre istatistiksel olarak anlamlı farklılık gösterdi (p=0,0023). Her iki grup arasında risk artışı açısından demografik veriler, laboratuvar değerleri, cerrahi özellikler ve hastalık evresi açısından anlamlı bir fark olmadığı gözlendi. Bununla birlikte özellikle aile öyküsünde MK ve over kanseri OK olan hastaların TPK gelişimi açısından yakın takip edilmesi gerekmektedir.

Anahtar Kelimeler:

meme kanseri, tiroid kanseri, aile hikayesi

Is There an Increased Risk for Thyroid Cancer in Breast Cancer Patients? Retrospective Single Center Experience

Breast cancer (BC) and Thyroid Papillary Cancer (TPC) are known to be the two most common types of cancer in women. It is known that the development of TPC in patients with BC is increased compared to the normal population. However, studies on the evaluation of increased risk in this regard are limited. Within the scope of the current study, it was aimed to evaluate the risk factors of TPC development in patients diagnosed with BC. The data of patients who were operated for TPC between 2006 and 2018 were retrospectively compiled from the endocrine surgery database. Twenty-three patients with a previous diagnosis of BC and undergoing thyroidectomy for TPC were included in the study group. The same number of patients who had no history of other malignancies and who had undergone surgery for TPC constituted the control group. The two groups were compared in terms of family history, demographic data, laboratory values, surgical characteristics and disease stage. The mean age of the 46 patients evaluated in the study was 55.35±9.2. The median time to diagnosis of TPC after BC was 27 (0-275) months. There was no statistically significant difference between the two groups in terms of age, body mass index, and menstrual status, presence of hyperthyroidism and positivity of autoantibodies. Family history positivity was statistically significantly different in the MC+TPC group compared to the TPC group (p=0.0023). It was observed that there was no significant difference between the two groups in terms of demographic data, laboratory values, surgical characteristics and disease stage in terms of increased risk. However, especially patients with a family history of BC and ovarian cancer should be followed closely for the development of TPC.

Keywords:

breast cancer, thyroid cancer, family history,

PDF

___

1. Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast cancer: A common etiology? Cancer Epidemiol Biomarkers Prev. 2019;28(4):643-649.
2. An JH, Hwangbo Y, Ahn HY, et al. A Possible Association between Thyroid Cancer and Breast Cancer. Thyroid. 2015;25(12):1330-1338.
3. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM. Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis. Thyroid. 2007;17(12):S134-S135.
4. Dong L, Lu J, Zhao B, Wang W, Zhao Y. Review of the possible association between thyroid and breast carcinoma. World journal of surgical oncology 2018;16:130.
5. Justyna W. 乳鼠心肌提取 {HHS} {Public} {Access}. Physiol Behav. 2017;176(5):139-148.
6. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in Southeast England. Br J Cancer. 2001;84:435–40.
7. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature genetics 1997;16:64- 7.
8.Nielsen S.M , White MG. , Hong S. Et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta- Analysis , Cancer Epidemiol Biomarkers Prev. 2016;25(2): 231–238.
9. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat. 2000; 61:183–95.
10. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600–8.
11. Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol. 2014;32:1818-24.